GlassScriptPhysician profile
Holly R Mcfadden
NPI 1003200452
$3,819.35
in general payments reported to CMS, 2019-2025
51 companies · $825 in 2025
The $825 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $885 · 2022: $354 · 2023: $643 · 2024: $1,112 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $375.54 | 2021-2025 | |
| Daiichi Sankyo INC. | $299.49 | 2021-2025 | Enhertu, Injectafer |
| Incyte Corporation | $288.85 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $199.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $167.67 | 2021-2025 | Calquence, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $151.69 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $136.09 | 2021-2025 | |
| Abbvie INC. | $124.13 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $123.92 | 2021-2025 | Xpovio |
| Amgen INC. | $118.75 | 2021-2023 | Nplate, Vectibix, Kyprolis |
| Genmab U.S., INC. | $117.40 | 2021-2024 | Epkinly, Tivdak |
| Janssen Biotech, INC. | $103.37 | 2023-2025 | Talvey, Tecvayli, Rybrevant |
| Dendreon Pharmaceuticals LLC | $92.29 | 2021-2023 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $87.63 | 2021-2024 | Ninlaro, Alunbrig |
| Genentech USA, INC. | $84.78 | 2024-2025 | Polivy, Lunsumio, Columvi |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $81.30 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Seagen INC. | $81.29 | 2021-2023 | Tukysa, Adcetris |
| Tempus Ai, INC | $69.85 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $68.58 | 2021-2025 | Onivyde, Somatuline Depot |
| Genzyme Corporation | $67.34 | 2022-2025 | |
| Blueprint Medicines Corporation | $62.05 | 2021-2024 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $55.97 | 2021-2023 | Qinlock |
| Rigel Pharmaceuticals, INC. | $48.08 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Stemline Therapeutics INC. | $47.49 | 2024-2025 | Orserdu |
| Foundation Medicine, INC. | $47.21 | 2022-2023 | |
| Welch Allyn | $44.36 | 2021 | |
| Alexion Pharmaceuticals, INC. | $44.13 | 2021-2024 | Ultomiris |
| Morphosys, US INC. | $43.94 | 2023 | Monjuvi |
| Sobi, INC | $43.91 | 2022-2024 | |
| Lilly USA, LLC | $41.93 | 2021-2023 | |
| Eisai INC. | $40.60 | 2021-2024 | |
| Emd Serono, INC. | $38.93 | 2021-2024 | |
| Dova Pharmaceuticals | $30.92 | 2021 | |
| Legend Biotech USA INC. | $30.64 | 2025 | Carvykti |
| Beigene USA, INC. | $30.06 | 2021 | |
| Celgene Corporation | $29.95 | 2025 | Reblozyl |
| Pfizer INC. | $29.13 | 2025 | |
| Pharmaessentia USA Corporation | $28.95 | 2024 | Besremi |
| Beone Medicines USA, INC. | $27.28 | 2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $24.18 | 2023 | Clonoseq |
| Astellas Pharma US INC | $23.89 | 2025 | Vyloy |
| Tersera Therapeutics LLC | $21.08 | 2022 | |
| Exelixis INC. | $20.36 | 2024 | Cabometyx |
| Array Biopharma INC | $20.15 | 2021 | |
| Glaxosmithkline, LLC. | $18.81 | 2025 | Ojjaara |
| Pharmacosmos Therapeutics INC. | $17.45 | 2024 | Monoferric |
| Aveo Pharmaceuticals, INC. | $16.37 | 2025 | |
| Kite Pharma, INC. | $14.52 | 2021 | |
| Adc Therapeutics America, INC. | $13.63 | 2021 | |
| Acrotech Biopharma INC. | $12.02 | 2021 | |
| Gilead Sciences, INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.